Interestingly, oncogenic BRAF induced senescence in melanoma [16, 22–24] and, in many cases, BRAF inhibition by vemurafenib [25], dabrafenib [26] or encorafenib [27] reinforced the senescence phenotype instead to reverse it. Here, BRAF is linked to melanoma.